← Leaderboards
Minhyung Kim
Roswell Park Cancer Institute Corp
$236,225
Attributed
$472,450
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $257.7K · FY2018–19$500K$375K$250K$125K$0
'18
'19
Funding mix
By agency
NIH$472,450 · 1
By mechanism
R21$472,450 · 1
Top collaborators
- Elizabeth Repasky2 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Xuefang Cao$8,586,764
- Jee Eun Choi$120,842
- Elizabeth Repasky$12,725,917
- Hemn Mohammadpour$1,062,412
- Cameron Riker Macdonald$169,092
Others in their field
Other Emerging Leaders on “Adrenergic Beta-Agonists”
- Anthony J St Leger · University Of Pittsburgh At Pittsburgh$2,005,300
- Bhagirath Chaurasia · University Of Iowa$1,915,515
- Steffen Lindert · Ohio State University$1,453,001
- Paul Cohen · Rockefeller University$1,290,756
- Christoph Daniel Rau · Univ Of North Carolina Chapel Hill$866,648
- Elizabeth L Kramer · Cincinnati Childrens Hosp Med Ctr$820,800
Research focus
Adrenergic Beta-AgonistsAdrenergic ReceptorAffectAgonistAllogenicAllograftingAllograft RejectionAllotransplantAnti-InflammatoryBeta-2 Adrenergic ReceptorsBeta-Adrenergic ReceptorBindingBlood VesselsBody PartBoneBone MarrowBone Marrow TransplantationCadaverCardiovascular SystemCatecholaminesCd8-Positive T-LymphocytesCell CompartmentationCellsAdrenergic Agents
Grant awards (2)
Activating adrenergic receptors to suppress the anti-graft immune response and improve survival of composite tissue allografts$214,750
R21 · FY2019 · AI
Activating adrenergic receptors to suppress the anti-graft immune response and improve survival of composite tissue allografts$257,700
R21 · FY2018 · AI